Quick Takeaways
- T. Rowe Price Investment Management, Inc. filed SCHEDULE 13G/A for KARYOPHARM THERAPEUTICS INC COMMON STOCK (KPTI).
- Disclosed ownership: 12%.
- Date of event: 31 Dec 2025.
T. Rowe Price Investment Management, Inc. - 31 Dec 2025 SCHEDULE 13G/A Report for KARYOPHARM THERAPEUTICS INC COMMON STOCK (KPTI)
- Filing Manager
- T. Rowe Price Investment Management, Inc.
- Reporting Manager
- T. Rowe Price Investment Management, Inc.
- Symbol
- KPTI
- Shares outstanding
- 19,020,517 shares
- Disclosed Ownership
- 2,244,421 shares
- Ownership
- 12%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 10:28:30 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 07 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"T. Rowe Price Investment Management, Inc. disclosed 12% ownership in KARYOPHARM THERAPEUTICS INC COMMON STOCK (KPTI) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 07 Nov 2025.
- Current filing was accepted on 17 Feb 2026, 10:28.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 12% | 2,244,421 | 1,491,409 | 0 | Ellen York | Vice President |